pharmaphorum

DECEMBER 13, 2021

The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. Meanwhile, Moderna started phase I/II trials of its mRNA-based influenza vaccine and announced plans to develop a combination mRNA vaccine targeting flu, covid and respiratory syncytial virus (RSV) in a single shot.

Vaccines 105

Vaccines Packaging 105

ISPE

JULY 7, 2023

Merck is currently conducting GMP runs of a BCM process for mAbs so that they can develop a process that can produce sufficient material for phase 1 clinical trials. This poses a challenge for resources, as many experiments are needed for a typical UF/DF study. Chemical Engineering Science (2021): 231. 2 Kokai-Kun, J. 3 Kokai-Kun, J.

FDA 52

FDA Pharmaceutical Companies Pharmaceutical Companies 52

The Thyroid Pharmacist

DECEMBER 7, 2022

Along with proactively filtering out indoor toxins , such as formaldehyde , commonly found in the home, and identifying and removing mold (in an old, front-loading washer and dryer), I have chosen to get rid of many everyday household products, once I identify that they contain toxic chemicals. One such product was my mattress!

Health and Personal Care Stores 54

Health and Personal Care Stores Labelling Immunization Compounding 54

The Thyroid Pharmacist

SEPTEMBER 15, 2023

While my own thyroid journey started much earlier (likely around puberty), and my thyroid hormones were well balanced in my 30s thanks to taking charge of my own health, I had a dreaded health flare in 2020. I also developed skin issues, anxiety, irritability, weight gain, and insomnia, and had super heavy periods twice per month.

Health and Personal Care Stores 56

Health and Personal Care Stores Dosage Compounding Immunization 56

PharmaShots

APRIL 26, 2023

Some of the alternative drugs for Dupixent include: Dupixent Pipeline Analysis6 PharmaShots presents a thorough analysis of the Dupixent pipeline, including ongoing Phase II and Phase III/ registration studies for various indications. These are a few key resources to understand healthcare services and policies.

Dosage 56

Dosage FDA 56

ISPE

SEPTEMBER 11, 2023

Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5102 (19CP02) in RR NHL.” Stability Evaluation of Hydrogen Peroxide Uptake Samples from Monoclonal Antibody Drug Product Aseptically Filled in Vapor Phase Hydrogen Peroxide-Sanitized Barrier Systems: A Case Study.” 1 (2021):7200.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

Pharmaceutical Technology

JANUARY 20, 2023

Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development. Process intensification is essentially producing more product with fewer resources.

Documentation 52

Documentation Communication 52

European Pharmaceutical Review

DECEMBER 20, 2022

Instead of using an event-based primary endpoint to study the impact of potassium-removing therapy in patients with CKD in the Phase III STABILIZE‑CKD trial, we are using reduction in estimated glomerular filtration rate (eGFR) over time as an indicator of slowing of disease progression.

Patient Care 102

Patient Care Hospitals Vaccines 102

Pharmaceutical Technology

MARCH 24, 2023

Unfortunately, lack of funding and resources remain an obstacle within the TB field for developing new vaccines. New Developments for TB In a recent Phase I clinical trial (NCT03722472), researchers have been able to test the first thermostable TB vaccine in patients. The BCG vaccine is a live-attenuated virus vaccine.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Communication 64

Pharmaceutical Technology

JUNE 20, 2023

DICE currently has two oral IL-17 inhibitors in clinical development; DC-806 is in Phase II trials for plaque psoriasis treatment, and DC-856 is in a Phase I for psoriasis.Acquiring these treatments could pave the way for Lilly to enter the highly competitive psoriasis market , where AbbVie, Pfizer and Johnson & Johnson have already clashed.

Communication 52

Communication 52

Pharmaceutical Technology

MARCH 23, 2023

Florham Park, New Jersey-based Exeltis Pharmaceuticals is currently running a Phase III study (EudraCT-2021-002178-17) with LPRI-421, a fixed dose combination of dienogest, a synthetic progesterone, and ethinylestradiol, a synthetic estrogen. The study’s results are anticipated for release in mid-2023. More research is needed.

Communication 52

Communication 52